TrialChinese medical journal2020

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.

Feng Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.